Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Regenerative Medicine Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for EPHB3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EPHB3 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View EPHB3 Products |
| Gene Delivery | EPHB3 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and surface expression validation. |
View EPHB3 Products |
| Benchmark Ab | Anti-EPHB3 Recombinant Antibody Recombinant positive control derived from public clinical-stage sequences. |
View EPHB3 Products |
| Validator | EPHB3 siRNA Set For target knockdown verification and functional specificity controls. |
View EPHB3 Products |
| Related Target A | EFNB2 Primary high-affinity ligand for EPHB3; essential for ligand-induced activation and internalization assays. |
View EFNB2 Products |
| Related Target B | EPHB4 Closely related homolog; critical for counter-screening to ensure antibody and small molecule selectivity. |
View EPHB4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus EPHB3 ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Subfamily counter screening (EphB1/B2/B4) | Homolog panel proteins strictly sequence-verified and expressed in HEK293 to preserve native glycosylation. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) available for direct assay calibration. |
| False Positives in Screening | Sequence-specific validated siRNA included for functional knockdown validation. |
Live EPHB3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EPHB3 therapeutics is intensifying, with major players shifting focus from traditional naked monoclonal antibodies to Antibody-Drug Conjugates (ADCs) and multi-specific constructs. EPHB3 is overexpressed in various solid tumors, including colorectal, lung, and head and neck cancers, while maintaining restricted normal tissue distribution. As first-generation therapies reach the clinic, the next wave of R&D is targeting tumor-specific internalization kinetics and bispecific combinations to overcome resistance pathways and minimize off-target toxicities within the Eph receptor family.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC (Antibody-Drug Conjugate) | Biotech & Pharma Consortia | Colorectal Cancer, NSCLC | Internalization Assay (Requires high-purity, native-glycosylated ECD-Fc to monitor ligand-induced endocytosis) |
| Bispecific / Multispecific | Oncology-focused Biotechs | Solid Tumors | Heterodimer Validation (Requires highly specific EPHB3 and EPHB4/EFNB2 proteins for dual-binding affinity profiling) |
| Monoclonal Antibody | Academic & Clinical Institutes | Fibrosis, Synaptic Disorders | Selectivity Assay (Requires comprehensive Eph receptor subfamily panels to rule out off-target binding) |